• 9.6k views

Education Initiative by

HMOs and gut development: A latest clinical Update

The effects of Human Milk Oligosaccharides (HMOs) on the infant gut are profound, influencing gut microbiome development and health trajectories through toddlerhood. Various HMOs, their doses, and periods of supplementation have been investigated, with clinical evidence supporting the supplementation of five key HMOs. HMOs are now incorporated into infant formula to mimic the benefits of breast milk, while non-human oligosaccharides are also explored for their potential benefits. Safety profiles and regulatory considerations are critical in the use of HMOs, which has advanced through improved synthesis and production techniques for clinical application. Real-world examples and case studies demonstrate the benefits of HMOs, and ongoing research is uncovering new possibilities for their application in promoting infant gut health.

About the Speaker

Dr. Sunil Kumar Sehgal Profile Image

Dr. Sunil Kumar Sehgal

 Consultant Pediatrician, Safdarjung Enclave, Delhi

Dr Sunil Kumar Sehgal, a distinguished pediatrician in Safdarjung Enclave, Delhi, brings 44 years of rich experience to his practice at Dr Sehgal’s Clinic. He completed his MBBS from Maulana Azad Medical College, New Delhi, in 1980, followed by a Diploma in Child Health (DCH) in 1983 from the same institution. Dr Sehgal furthered his education with an MD in pediatrics from Safdarjung Hospital, University of Delhi, in 1985. His extensive training and expertise underscore his commitment to providing high-quality care for children and families in the community.

Education Initiative by

Upcoming Case Discussions

Leave a Comment

Your email address will not be published.

Author Post

authorimage

Impact

+

Talks

+

webinar

+

no.of registrations

One liner about speaker

Why is speaker relevant?

Dr. Sunil Kumar Sehgal's Talks on Assimilate

webinar
Dr. Sunil Kumar Sehgal
  • 17th-July-2024, TIME : 4:00PM TO 5:00 PM
  • 0

The effects of Human Milk Oligosaccharides (HMOs) on the infant gut are profound, influencing gut microbiome development and health trajectories through toddlerhood. Various HMOs, their doses, and periods of supplementation have been investigated, with clinical evidence supporting the supplementation of five key HMOs. HMOs are now incorporated into infant formula to mimic the benefits of breast milk, while non-human oligosaccharides are also explored for their potential benefits. Safety profiles and regulatory considerations are critical in the use of HMOs, which has advanced through improved synthesis and production techniques for clinical application. Real-world examples and case studies demonstrate the benefits of HMOs, and ongoing research is uncovering new possibilities for their application in promoting infant gut health.